Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
August 09, 2022 02:00 ET
|
Verona Pharma plc
Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24 weeks Well tolerated with safety results similar to placebo Conference call...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD
August 08, 2022 16:30 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update
July 29, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
June 09, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma to Host KOL Event on June 16, 2022
June 06, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on...
Verona Pharma to Present at Jefferies Healthcare Conference
May 25, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a...
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
May 09, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Announces May 2022 Investor Conference Participation
May 04, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022: ...
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 03, 2022 02:00 ET
|
Verona Pharma plc
Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022 James Brady joined the Board as Non-Executive Director Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
April 19, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...